查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1649463

表观遗传学药物和诊断市场 - 预测 2025 年至 2030 年

Epigenetics Drugs and Diagnostic Technologies Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 146 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

表观遗传药物和诊断市场预计将以 15.21% 的复合年增长率成长，从 2025 年的 262.83 亿美元成长至 2030 年的 533.45 亿美元。

表观遗传诊断研究在不改变 DNA 序列本身的情况下遗传、细胞和身体特征的变化。该领域是各种变化的指标，在发育生物学中发挥重要作用。表观遗传药物和诊断技术市场的发展受到糖尿病和肥胖等疾病发病率上升的推动，这些疾病与发炎、代谢、心血管和肿瘤疾病有关。此外，表观遗传学与精神健康状况的诊断越来越相关。由于基因表现对行为有深远的影响，科学家可以探索神经遗传学如何受到环境因素的影响。这项研究可以帮助我们更好地理解成瘾和忧郁症等问题。人们对个人基因组学的兴趣日益浓厚，使得收集个人表观遗传资料和核酸定序变得更加容易，使消费者更容易获得个人化医疗。随着 DNA资料的增长，表观遗传检测将能够支持研究并透过个人化医疗方法提供价值。

表观遗传药物与诊断市场驱动因素：

  • 癌症患者数量的增加：全球癌症患者数量的增加是推动表观遗传药物和诊断技术市场成长的主要因素。根据美国癌症协会（ACS）预测，2022年全球将有2,020万癌症新病例和970万癌症死亡病例，其中乳癌、肺癌、摄护腺癌、大肠直肠癌和胃癌占比接近50%。

研究表明，癌症进展通常与表观遗传异常和基因变化有关。癌症研究表观遗传学的进展集中在 DNA 甲基化、组蛋白修饰、核小体定位和非编码 RNA（如微型RNA表达）等领域。因此，表观遗传治疗应运而生。例如，Galleri 测试等测试透过识别癌症特异性的甲基化模式来提高诊断能力，将筛检从常规筛检扩展到胰腺癌和卵巢癌等癌症。

影响表观遗传药物和诊断市场的地理趋势：

  • 亚太地区快速成长：表观遗传药物和诊断技术市场分为北美、南美、欧洲、中东和非洲以及亚太地区。在预测期内，由于中国、日本、印度和韩国等新兴经济体数量不断增加，推动医疗保健基础设施的发展，亚太地区预计将成为该市场成长最快的地区。

例如，2022年中国将报告约482万例新发癌症病例和257万例癌症死亡病例。该地区慢性病患病率的不断上升预计将推动对錶观遗传学相关的先进诊断技术的需求。另一方面，北美凭藉其先进的医疗保健基础设施预计将占据市场的大部分份额。神经系统疾病的高发生率也助长了这种增长。预测表明，未来几年阿兹海默症症等疾病将影响数百万人。摘要，表观遗传药物和诊断市场将迎来显着增长，这得益于全球癌症发病率的上升、人们对早期诊断选择的认识的不断提高、表观遗传研究和技术的进步、政府在医疗保健投资方面的支持性倡议以及特别是亚太地区的有利区域趋势，这些都加强了这一不断扩大的市场环境。

为什么要购买这份报告？

  • 深刻分析：获得深入的市场洞察，涵盖主要和新兴地区，重点关注客户群、政府政策和社会经济因素、消费者偏好、垂直行业和其他子区隔。
  • 竞争格局：了解全球主要企业所采用的策略策略，并了解正确策略带来的潜在市场渗透率。
  • 市场趋势和驱动因素：探索动态因素和关键市场趋势以及它们将如何影响未来的市场发展。
  • 可行的建议：利用洞察力做出策略决策，在动态环境中开闢新的业务流和收益。
  • 适合广泛用户：对于新兴企业、科学研究机构、顾问公司、中小企业和大型企业来说都是有益且具成本效益的。

它有什么用途？

产业与市场考量、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本支出决策、法律规范与影响、新产品开发、竞争影响

研究范围

  • 2022 年至 2030 年的历史资料与预测
  • 成长机会、挑战、供应链前景、法规结构、客户行为和趋势分析
  • 竞争定位、策略和市场占有率分析
  • 收益成长和预测分析包括国家在内的细分市场和地区
  • 公司概况（尤其是主要趋势）

表观遗传药物和诊断市场细分如下：

按药物

  • 组蛋白去乙酰化酶 (HDAC) 抑制剂
  • DNA甲基转移酵素(DNMT) 抑制剂
  • 其他的

依技术分类

  • 试剂
  • 套件
  • 晶片定序试剂套件
  • 全基因组扩增试剂套件
  • 亚硫酸盐转化试​​剂套件
  • RNA定序套件
  • 装置
  • 服务
  • 其他的

按应用

  • 肿瘤疾病
  • 非肿瘤疾病
  • 发炎性疾病
  • 代谢紊乱
  • 传染病
  • 心血管疾病
  • 其他的

按地区

  • 北美洲
  • 美国
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 南美洲其他地区
  • 欧洲
  • 英国
  • 德国
  • 法国
  • 义大利
  • 西班牙
  • 其他欧洲国家
  • 中东和非洲
  • 沙乌地阿拉伯
  • UAE
  • 其他中东和非洲地区
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 台湾
  • 泰国
  • 印尼
  • 其他亚太地区

目录

第 1 章 简介

  • 市场概况
  • 市场定义
  • 研究范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益

第二章调查方法

  • 研究设计
  • 研究过程
  • 资料检验

第三章执行摘要

  • 主要发现
  • 分析师观点

第四章 市场动态

  • 市场驱动因素
  • 市场限制
  • 波特五力分析
  • 产业价值链分析

第 5 章表观遗传药物和诊断市场（按药物）

  • 介绍
  • 组蛋白去乙酰化酶 (HDAC) 抑制剂
  • DNA甲基转移酵素(DNMT) 抑制剂
  • 其他的

6. 表观遗传药物和诊断市场（按技术）

  • 介绍
  • 试剂
  • 套件
    • 晶片定序试剂套件
    • 全基因组扩增试剂套件
    • 亚硫酸盐转化试​​剂套件
    • RNA定序套件
  • 装置
  • 服务
  • 其他的

第七章表观遗传学药物和诊断市场（按应用）

  • 介绍
  • 肿瘤疾病
  • 非肿瘤疾病
    • 发炎性疾病
    • 代谢紊乱
    • 感染疾病
    • 心血管疾病
    • 其他的

8. 表观遗传药物和诊断市场（按地区）

  • 世界概况
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲国家
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 台湾
    • 泰国
    • 印尼
    • 其他亚太地区

第九章竞争格局及分析

  • 主要企业和策略分析
  • 新兴企业和市场盈利
  • 合併、收购、协议和合作
  • 竞争仪錶板

第十章 公司简介

  • Roche Diagnostics
  • Thermo Fisher Scientific, Inc.
  • Element Biosciences, Inc.
  • Dovetail Genomics LLC.
  • Abcam plc.
  • Eisai Co., Ltd.
  • Novartis AG
  • Cantata Bio
  • Illumina, Inc.
  • Promega Corporation
  • Merck KGaA
简介目录
Product Code: KSI061617239

The epigenetics drugs and diagnostic technologies market is expected to grow at a CAGR of 15.21%, reaching a market size of US$53.345 billion in 2030 from US$26.283 billion in 2025.

Epigenetics diagnosis involves studying changes in genetic, cellular, and physical characteristics without altering the DNA sequence itself. This field serves as an indicator of various changes and plays a vital role in developmental biology. The market for epigenetics drugs and diagnostic technologies is driven by the rising incidence of disorders such as diabetes and obesity, which are linked to inflammatory, metabolic, cardiovascular, and oncological diseases.Moreover, epigenetics is increasingly relevant in diagnosing mental health conditions. Gene expression significantly influences behavior, allowing scientists to explore neurogenetics shaped by environmental factors. This research can enhance understanding of issues like addiction and depression. The growing interest in personal genomics facilitates the collection of individual epigenetic data and DNA sequencing, making personalized medicine more attainable for consumers. As data on DNA increases, epigenetic testing becomes more capable of supporting research and delivering value through tailored medical approaches.

Drivers of the Epigenetics Drugs and Diagnostic Technologies Market:

  • Rising Incidence of Cancer Cases: The global increase in cancer cases is a major factor propelling growth in the epigenetics drugs and diagnostic technologies market. According to the American Cancer Society (ACS), there were 20.2 million new cancer cases and 9.7 million cancer deaths worldwide in 2022, with prevalent cancers including breast, lung, prostate, colorectal, and stomach cancers-accounting for nearly 50% of total cases.

Research has shown that cancer progression is often associated with epigenetic abnormalities alongside genetic changes. Epigenetic advancements in cancer research focus on areas such as DNA methylation, histone modifications, nucleosome positioning, and non-coding RNAs like microRNA expression. This has led to the emergence of epigenetic therapies. For example, tests like the Galleri test improve diagnostic capabilities by identifying cancer-specific methylation patterns and extending screening beyond routine methods to include cancers such as pancreatic and ovarian cancer.

Geographical Trends Shaping the Epigenetics Drugs and Diagnostic Technologies Market:

  • Rapid Growth in Asia-Pacific: The epigenetics drugs and diagnostic technologies market is segmented into regions including North America, South America, Europe, the Middle East and Africa, and Asia-Pacific. During the forecast period, Asia-Pacific is expected to be the fastest-growing region in this market due to emerging economies like China, Japan, India, and South Korea driving healthcare infrastructure development.

For instance, approximately 4.82 million new cancer cases and 2.57 million cancer deaths were reported in China in 2022. The increasing prevalence of chronic diseases in this region is expected to propel demand for advanced diagnostic technologies related to epigenetics.Meanwhile, North America is projected to maintain a significant share of the market due to its advanced healthcare infrastructure. The high prevalence of neurological disorders contributes to this growth; projections indicate that there will be millions affected by conditions like Alzheimer's disease in the coming years. Furthermore, substantial government investments alongside private sector initiatives are expected to drive continued regional expansion.In summary, the epigenetics drugs and diagnostic technologies market is poised for significant growth driven by rising cancer incidence rates globally, increasing awareness about early diagnosis options, advancements in epigenetic research and technology, supportive governmental initiatives in healthcare investment, and favorable geographical trends-particularly within Asia-Pacific-that enhance this expanding market landscape.

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

Epigenetics Drugs And Diagnostic Technologies Market has been segmented as following:

By Drugs

  • Histone Deacetylase (HDAC) Inhibitors
  • DNA Methyltransferase (DNMT) Inhibitors
  • Others

By Technology

  • Reagents
  • Kits
  • Chip Sequencing Kit
  • Whole Genomic Amplification Kit
  • Bisulfite Conversion Kit
  • RNA Sequencing Kit
  • Instruments
  • Services
  • Others

By Application

  • Oncology
  • Non-oncology
  • Inflammatory Diseases
  • Metabolic Diseases
  • Infectious Diseases
  • Cardiovascular Diseases
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Rest of South America
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Rest of the Middle East and Africa
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Rest of Asia-Pacific

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Process
  • 2.3. Data Validation

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. Analyst View

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Supplier
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET BY DRUGS

  • 5.1. Introduction
  • 5.2. Histone Deacetylase (HDAC) Inhibitors
  • 5.3. DNA Methyltransferase (DNMT) Inhibitors
  • 5.4. Others

6. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET BY TECHNOLOGY

  • 6.1. Introduction
  • 6.2. Reagents
  • 6.3. Kits
    • 6.3.1. Chip Sequencing Kit
    • 6.3.2. Whole Genomic Amplification Kit
    • 6.3.3. Bisulfite Conversion Kit
    • 6.3.4. RNA Sequencing Kit
  • 6.4. Instruments
  • 6.5. Services
  • 6.6. Others

7. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET BY APPLICATION

  • 7.1. Introduction
  • 7.2. Oncology
  • 7.3. Non-oncology
    • 7.3.1. Inflammatory Diseases
    • 7.3.2. Metabolic Diseases
    • 7.3.3. Infectious Diseases
    • 7.3.4. Cardiovascular Diseases
    • 7.3.5. Others

8. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET BY GEOGRAPHY

  • 8.1. Global Overview
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Rest of South America
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Italy
    • 8.4.5. Spain
    • 8.4.6. Rest of Europe
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. United Arab Emirates
    • 8.5.3. Rest of the Middle East and Africa
  • 8.6. Asia-Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Taiwan
    • 8.6.6. Thailand
    • 8.6.7. Indonesia
    • 8.6.8. Rest of Asia-Pacific

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Emerging Players and Market Lucrativeness
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Roche Diagnostics
  • 10.2. Thermo Fisher Scientific, Inc.
  • 10.3. Element Biosciences, Inc.
  • 10.4. Dovetail Genomics LLC.
  • 10.5. Abcam plc.
  • 10.6. Eisai Co., Ltd.
  • 10.7. Novartis AG
  • 10.8. Cantata Bio
  • 10.9. Illumina, Inc.
  • 10.10. Promega Corporation
  • 10.11. Merck KGaA